The latest update is out from InMed Pharmaceuticals (INM).
The Company has revealed promising preclinical data for INM-089, which shows potential in treating dry Age-Related Macular Degeneration (AMD), stirring interest among investors eyeing developments in the biotech sector. This announcement, while significant, will not be filed officially with regulatory authorities but is intended to keep the market informed about the progress of their research.
See more insights into INM stock on TipRanks’ Stock Analysis page.
